Literature DB >> 19142036

Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori.

Shoji Suzuki1, Hidekazu Suzuki, Toshihiro Nishizawa, Fumihiko Kaneko, Sumire Ootani, Hiroe Muraoka, Yoshimasa Saito, Intetsu Kobayashi, Toshifumi Hibi.   

Abstract

BACKGROUND: Recently, the number of Helicobacter pylori isolates showing antibiotic resistance has been increasing. Rifabutin (RFB) is one of the possible candidates for H. pylori eradication. In the present study, the RFB minimum inhibitory concentrations (MICs) and the resistance-determining genes to RFB (rpoB) were examined to clarify the relationship between drug MICs, rpoB mutations, and past history of rifampicin (RFP) treatment.
METHODS: The MICs of RFB and rpoB mutations were examined for 48 strains with failure of H. pylori eradication in the University Hospital and 46 isolated from patients at a specialized hospital for chronic respiratory diseases without past H. pylori eradication. Past RFP treatment was also examined.
RESULTS: Eight of 94 strains showed high RFB MICs and 6 of the 8 strains showed rpoB point mutations. Although no strains showed high RFB MICs among 48 strains from the patients in the University Hospital, all 7 strains isolated from patients with past RFP treatment showed high RFB MICs (>or=0.12 mg/l).
CONCLUSION: Although RFB might be a potential candidate component of a new H. pylori eradication regimen following the first- or second-line failure, it should be used after examining a past history of RFP treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19142036     DOI: 10.1159/000191204

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  18 in total

1.  Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection.

Authors:  Sander Veldhuyzen van Zanten; Snehal Desai; Linda Best; Geraldine Cooper-Lesins; Dickran Malatjalian; David Haldane; Kevork Peltekian
Journal:  Can J Gastroenterol       Date:  2010-05       Impact factor: 3.522

Review 2.  Helicobacter pylori and gastric cancer.

Authors:  Hidekazu Suzuki; Eisuke Iwasaki; Toshifumi Hibi
Journal:  Gastric Cancer       Date:  2009-06-27       Impact factor: 7.370

3.  Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Hitoshi Tsugawa; Seiichiro Fukuhara; Sawako Miyoshi; Kenro Hirata; Takashi Seino; Misako Matsushita; Toshihiro Nishizawa; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2015-11-13       Impact factor: 4.623

Review 4.  Second and third line treatment options for Helicobacter pylori eradication.

Authors:  Mingjun Song; Tiing Leong Ang
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

5.  Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Takama Maekawa; Naohiko Harada; Tatsuya Toyokawa; Toshio Kuwai; Masanori Ohara; Takahiro Suzuki; Masahiro Kawanishi; Kenji Noguchi; Toshiyuki Yoshio; Shinji Katsushima; Hideo Tsuruta; Eiji Masuda; Munehiro Tanaka; Shunsuke Katayama; Norio Kawamura; Yuko Nishizawa; Toshifumi Hibi; Masahiko Takahashi
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

6.  Helicobacter pylori resistance to rifabutin in the last 7 years.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Juntaro Matsuzaki; Hiroe Muraoka; Hitoshi Tsugawa; Kenro Hirata; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2011-09-06       Impact factor: 5.191

Review 7.  Current recommendations for Helicobacter pylori therapies in a world of evolving resistance.

Authors:  Francis Mégraud
Journal:  Gut Microbes       Date:  2013-08-05

Review 8.  Treatment of Helicobacter pylori infection: current status and future concepts.

Authors:  Jyh-Chin Yang; Chien-Wei Lu; Chun-Jung Lin
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

Review 9.  Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.

Authors:  Evariste Tshibangu-Kabamba; Yoshio Yamaoka
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-17       Impact factor: 46.802

10.  Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication.

Authors:  Wenming Wu; Yunsheng Yang; Gang Sun
Journal:  Gastroenterol Res Pract       Date:  2012-07-05       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.